{"protocolSection": {"identificationModule": {"nctId": "NCT01076088", "orgStudyIdInfo": {"id": "0431-121"}, "secondaryIdInfos": [{"id": "2010_514", "type": "OTHER", "domain": "Merck Registration Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)", "officialTitle": "A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-11-15", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2012-12-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-24", "studyFirstSubmitQcDate": "2010-02-24", "studyFirstPostDateStruct": {"date": "2010-02-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-12-17", "resultsFirstSubmitQcDate": "2013-12-17", "resultsFirstPostDateStruct": {"date": "2014-02-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-27", "lastUpdatePostDateStruct": {"date": "2017-05-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China. The primary hypothesis is that after 24 weeks, initial co-administration treatment with sitagliptin and metformin provided greater reduction in hemoglobin A1C (A1C) compared to initial treatment with sitagliptin alone and with metformin alone."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 744, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin 50 mg + metformin 500 mg", "type": "EXPERIMENTAL", "description": "Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.", "interventionNames": ["Drug: Sitagliptin 50 mg", "Drug: Metformin 500 mg"]}, {"label": "Sitagliptin 50 mg + metformin 850 mg", "type": "EXPERIMENTAL", "description": "Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.", "interventionNames": ["Drug: Sitagliptin 50 mg", "Drug: Metformin 850 mg"]}, {"label": "Metformin 500 mg", "type": "ACTIVE_COMPARATOR", "description": "Metformin 500 mg twice daily for 24 weeks.", "interventionNames": ["Drug: Metformin 500 mg"]}, {"label": "Metformin 850 mg", "type": "ACTIVE_COMPARATOR", "description": "Metformin 850 mg twice daily for 24 weeks.", "interventionNames": ["Drug: Metformin 850 mg"]}, {"label": "Sitagliptin 100 mg", "type": "EXPERIMENTAL", "description": "Sitagliptin 100 mg once daily for 24 weeks.", "interventionNames": ["Drug: Sitagliptin 100 mg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching placebo tablets for 24 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin 50 mg", "description": "Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.", "armGroupLabels": ["Sitagliptin 50 mg + metformin 500 mg", "Sitagliptin 50 mg + metformin 850 mg"], "otherNames": ["Januvia\u00ae, Tesavel\u00ae, Xelevia\u00ae, Ristaben\u00ae"]}, {"type": "DRUG", "name": "Metformin 500 mg", "description": "Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.", "armGroupLabels": ["Metformin 500 mg", "Sitagliptin 50 mg + metformin 500 mg"], "otherNames": ["Fortamet\u00ae, Glucophage\u00ae, Glucophage\u00ae XR, Glumetza\u00ae, Riomet\u00ae, Metgluco\u00ae, Glycoran\u00ae"]}, {"type": "DRUG", "name": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily for 24 weeks.", "armGroupLabels": ["Sitagliptin 100 mg"], "otherNames": ["Januvia\u00ae, Tesavel\u00ae, Xelevia\u00ae, Ristaben\u00ae"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo tablets to sitagliptin or metformin for 24 weeks.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Metformin 850 mg", "description": "Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.", "armGroupLabels": ["Metformin 850 mg", "Sitagliptin 50 mg + metformin 850 mg"], "otherNames": ["Fortamet\u00ae, Glucophage\u00ae, Glucophage\u00ae XR, Glumetza\u00ae, Riomet\u00ae, Metgluco\u00ae, Glycoran\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (A1C) at Week 24", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24", "description": "Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.", "timeFrame": "Baseline and Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* has type 2 diabetes mellitus\n* is male, a female who cannot have children, or a female who agrees to use birth control during the study\n* is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \\[A1C\\] 7.5-11.0%) or on oral single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)\n\nExclusion Criteria:\n\n* Patient has type 1 diabetes mellitus or ketoacidosis\n* Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)\n* Patient is on a weight loss program not in the maintenance phase or on a weight loss medication\n* Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer\n* Patient is HIV positive\n* Patient is pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "27181998", "type": "RESULT", "citation": "Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, O'Neill EA, Golm GT, Engel SS, Kaufman KD, Shankar RR. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016 Sep;7(5):727-36. doi: 10.1111/jdi.12511. Epub 2016 May 19."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "In total, 744 participants were randomized to treatment. Of these 744 participants, 1 participant, assigned to the placebo group, did not receive study medication. This participant was not included in the safety analyses.", "groups": [{"id": "FG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily"}, {"id": "FG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily"}, {"id": "FG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily"}, {"id": "FG003", "title": "Metformin 850", "description": "Metformin 850 mg twice daily"}, {"id": "FG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily"}, {"id": "FG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin. Population includes 1 participant who did not receive any study medication."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "125"}, {"groupId": "FG002", "numSubjects": "126"}, {"groupId": "FG003", "numSubjects": "124"}, {"groupId": "FG004", "numSubjects": "120"}, {"groupId": "FG005", "numSubjects": "127"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "107"}, {"groupId": "FG002", "numSubjects": "109"}, {"groupId": "FG003", "numSubjects": "109"}, {"groupId": "FG004", "numSubjects": "104"}, {"groupId": "FG005", "numSubjects": "104"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "17"}, {"groupId": "FG003", "numSubjects": "15"}, {"groupId": "FG004", "numSubjects": "16"}, {"groupId": "FG005", "numSubjects": "23"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "3"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "2"}]}, {"type": "Non-compliance with study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "10"}, {"groupId": "FG004", "numSubjects": "11"}, {"groupId": "FG005", "numSubjects": "17"}]}, {"type": "Other protocol specified criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily"}, {"id": "BG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily"}, {"id": "BG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily"}, {"id": "BG003", "title": "Metformin 850", "description": "Metformin 850 mg twice daily"}, {"id": "BG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily"}, {"id": "BG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin. Population includes 1 participant who did not receive any study medication."}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "126"}, {"groupId": "BG003", "value": "124"}, {"groupId": "BG004", "value": "120"}, {"groupId": "BG005", "value": "127"}, {"groupId": "BG006", "value": "744"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.6", "spread": "11.3"}, {"groupId": "BG001", "value": "52.4", "spread": "9.3"}, {"groupId": "BG002", "value": "52.6", "spread": "9.5"}, {"groupId": "BG003", "value": "53.0", "spread": "10.3"}, {"groupId": "BG004", "value": "51.7", "spread": "10.2"}, {"groupId": "BG005", "value": "53.6", "spread": "9.7"}, {"groupId": "BG006", "value": "52.7", "spread": "10.0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "57"}, {"groupId": "BG003", "value": "49"}, {"groupId": "BG004", "value": "46"}, {"groupId": "BG005", "value": "40"}, {"groupId": "BG006", "value": "287"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "69"}, {"groupId": "BG003", "value": "75"}, {"groupId": "BG004", "value": "74"}, {"groupId": "BG005", "value": "87"}, {"groupId": "BG006", "value": "457"}]}]}]}, {"title": "Hemoglobin A1c (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of glycosylated hemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.46", "spread": "0.97"}, {"groupId": "BG001", "value": "8.66", "spread": "0.95"}, {"groupId": "BG002", "value": "8.69", "spread": "0.99"}, {"groupId": "BG003", "value": "8.67", "spread": "1.08"}, {"groupId": "BG004", "value": "8.74", "spread": "1.14"}, {"groupId": "BG005", "value": "8.97", "spread": "1.05"}, {"groupId": "BG006", "value": "8.70", "spread": "1.04"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "175.6", "spread": "40.6"}, {"groupId": "BG001", "value": "181.9", "spread": "43.0"}, {"groupId": "BG002", "value": "184.6", "spread": "46.8"}, {"groupId": "BG003", "value": "183.5", "spread": "47.7"}, {"groupId": "BG004", "value": "182.5", "spread": "44.0"}, {"groupId": "BG005", "value": "185.8", "spread": "47.3"}, {"groupId": "BG006", "value": "182.3", "spread": "45.0"}]}]}]}, {"title": "2-hour post meal glucose (2-h PMG)", "description": "Participants with data: sita50/met500, n=121; sita50/met850, n=125; met500, n=125; met850, n=123; sita100, n=119; placebo; n=126; total, n=739", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "292.7", "spread": "81.2"}, {"groupId": "BG001", "value": "292.9", "spread": "68.4"}, {"groupId": "BG002", "value": "303.2", "spread": "74.1"}, {"groupId": "BG003", "value": "298.8", "spread": "74.6"}, {"groupId": "BG004", "value": "297.7", "spread": "74.7"}, {"groupId": "BG005", "value": "308.3", "spread": "83.6"}, {"groupId": "BG006", "value": "299.0", "spread": "76.2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (A1C) at Week 24", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.", "populationDescription": "Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for the A1C subsequent to at least 1 dose of study treatment, or lacked baseline data for the A1C. Last observation carried forward (missing data approach).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily"}, {"id": "OG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily"}, {"id": "OG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily"}, {"id": "OG003", "title": "Metformin 850 mg", "description": "Metformin 850 mg twice daily"}, {"id": "OG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "114"}, {"groupId": "OG002", "value": "116"}, {"groupId": "OG003", "value": "117"}, {"groupId": "OG004", "value": "113"}, {"groupId": "OG005", "value": "117"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.67", "lowerLimit": "-1.92", "upperLimit": "-1.43"}, {"groupId": "OG001", "value": "-1.83", "lowerLimit": "-2.07", "upperLimit": "-1.58"}, {"groupId": "OG002", "value": "-1.29", "lowerLimit": "-1.54", "upperLimit": "-1.04"}, {"groupId": "OG003", "value": "-1.56", "lowerLimit": "-1.80", "upperLimit": "-1.32"}, {"groupId": "OG004", "value": "-0.99", "lowerLimit": "-1.24", "upperLimit": "-0.75"}, {"groupId": "OG005", "value": "-0.59", "lowerLimit": "-0.84", "upperLimit": "-0.34"}]}]}], "analyses": [{"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.087", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "0.04"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.15", "ciUpperLimit": "-0.52"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.014", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.69", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.99", "ciUpperLimit": "-0.37"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-1.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.55", "ciUpperLimit": "-0.93"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 850 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.97", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.28", "ciUpperLimit": "-0.66"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-1.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.39", "ciUpperLimit": "-0.78"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 500 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.01", "ciUpperLimit": "-0.39"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "Pairwise comparison, sitagliptin 100 mg vs. placebo. The normality assumption required for validity of ANCOVA was violated due to a biologically implausible extreme outlier. See below for results using robust regression.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "-0.09"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in least squares mean", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.62", "ciUpperLimit": "-0.09"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.13", "ciUpperLimit": "-0.60"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.007", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "-0.10"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "-0.35"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-1.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.52", "ciUpperLimit": "-0.99"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.90", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.16", "ciUpperLimit": "-0.63"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-1.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.26", "ciUpperLimit": "-0.74"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.90", "ciUpperLimit": "-0.37"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "pValueComment": "Comparing co-administration with individual components. This is a post-hoc analysis using robust regression, a valid method in the presence of outliers.", "statisticalMethod": "Regression, Robust", "statisticalComment": "The Robust Regression model included terms for treatment and prior AHA therapy status (yes/no) and a covariate for baseline A1C.", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.65", "ciUpperLimit": "-0.12"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2-hour Post Meal Glucose (2-h PMG) at Week 24", "description": "Change from baseline in 2-h PMG at Week 24 is defined as Week 24 2-h PMG minus Week 0 2-h PMG.", "populationDescription": "Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for 2-h PMG subsequent to at least 1 dose of study treatment, or lacked baseline data for 2-h PMG. Last observation carried forward (missing data approach).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily"}, {"id": "OG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily"}, {"id": "OG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily"}, {"id": "OG003", "title": "Metformin 850", "description": "Metformin 850 mg twice daily"}, {"id": "OG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "110"}, {"groupId": "OG002", "value": "112"}, {"groupId": "OG003", "value": "108"}, {"groupId": "OG004", "value": "107"}, {"groupId": "OG005", "value": "107"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-97.05", "lowerLimit": "-109.01", "upperLimit": "-85.09"}, {"groupId": "OG001", "value": "-109.46", "lowerLimit": "-121.47", "upperLimit": "-97.44"}, {"groupId": "OG002", "value": "-65.67", "lowerLimit": "-77.76", "upperLimit": "-53.58"}, {"groupId": "OG003", "value": "-90.93", "lowerLimit": "-103.04", "upperLimit": "-78.83"}, {"groupId": "OG004", "value": "-48.11", "lowerLimit": "-60.37", "upperLimit": "-35.85"}, {"groupId": "OG005", "value": "-21.88", "lowerLimit": "-34.33", "upperLimit": "-9.43"}]}]}], "analyses": [{"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.017", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-18.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.75", "ciUpperLimit": "-3.29"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-61.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-76.61", "ciUpperLimit": "-46.07"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-31.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-46.49", "ciUpperLimit": "-16.28"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-48.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-64.21", "ciUpperLimit": "-33.67"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-87.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-102.87", "ciUpperLimit": "-72.27"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 850 mg vs. placebo", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-69.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-84.41", "ciUpperLimit": "-53.70"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-75.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-90.47", "ciUpperLimit": "-59.87"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 500 mg vs. placebo", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-43.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-58.99", "ciUpperLimit": "-28.58"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 100 mg vs. placebo", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline 2-H PMG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-26.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-41.62", "ciUpperLimit": "-10.84"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24", "description": "Change from baseline in FPG at Week 24 is defined as Week 24 FPG minus Week 0 FPG.", "populationDescription": "Full Analysis Set, all randomized participants except those who: failed to take at least 1 dose of study treatment, lacked all post-randomization data for FPG subsequent to at least 1 dose of study treatment, or lacked baseline data for FPG. Last observation carried forward (missing data approach).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily"}, {"id": "OG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily"}, {"id": "OG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily"}, {"id": "OG003", "title": "Metformin 850", "description": "Metformin 850 mg twice daily"}, {"id": "OG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily"}, {"id": "OG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "116"}, {"groupId": "OG002", "value": "119"}, {"groupId": "OG003", "value": "119"}, {"groupId": "OG004", "value": "114"}, {"groupId": "OG005", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-39.38", "lowerLimit": "-46.29", "upperLimit": "-32.47"}, {"groupId": "OG001", "value": "-47.74", "lowerLimit": "-54.73", "upperLimit": "-40.75"}, {"groupId": "OG002", "value": "-33.66", "lowerLimit": "-40.66", "upperLimit": "-26.66"}, {"groupId": "OG003", "value": "-39.63", "lowerLimit": "-46.50", "upperLimit": "-32.76"}, {"groupId": "OG004", "value": "-21.86", "lowerLimit": "-28.92", "upperLimit": "-14.80"}, {"groupId": "OG005", "value": "-11.93", "lowerLimit": "-18.94", "upperLimit": "-4.92"}]}]}], "analyses": [{"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.069", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. metformin 850 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-8.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.86", "ciUpperLimit": "0.64"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. sitagliptin 100 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-25.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.72", "ciUpperLimit": "-17.04"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.198", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. metformin 500 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-5.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.44", "ciUpperLimit": "3.00"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. sitagliptin 100 mg", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-17.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.33", "ciUpperLimit": "-8.72"}, {"groupIds": ["OG001", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 850 mg vs. placebo.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-35.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-44.56", "ciUpperLimit": "-27.06"}, {"groupIds": ["OG003", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 850 mg vs. placebo.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-27.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.40", "ciUpperLimit": "-19.00"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, sitagliptin 50 mg + metformin 500 mg vs. placebo.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-27.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.18", "ciUpperLimit": "-18.73"}, {"groupIds": ["OG002", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Pairwise comparison, metformin 500 mg vs. placebo.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-21.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.42", "ciUpperLimit": "-13.04"}, {"groupIds": ["OG004", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.027", "pValueComment": "Pairwise comparison, sitagliptin 100 mg vs. placebo.", "statisticalMethod": "ANCOVA", "statisticalComment": "The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (yes/no) and a covariate for baseline FPG.", "paramType": "Difference in Least Squares Mean", "paramValue": "-9.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.72", "ciUpperLimit": "-1.14"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All participants as treated population. Serious and non-serious adverse events (AEs) include and exclude data after rescue therapy, respectively. One event of hypoglycaemia that, per protocol, should have been reported as an AE was not reported as an AE. This event occurred in a participant who had another event of hypoglycaemia that was reported.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 50 mg + Metformin 500 mg", "description": "Sitagliptin 50 mg twice daily + metformin 500 mg twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 122, "otherNumAffected": 9, "otherNumAtRisk": 122}, {"id": "EG001", "title": "Sitagliptin 50 mg + Metformin 850 mg", "description": "Sitagliptin 50 mg twice daily + metformin 850 mg twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 125, "otherNumAffected": 14, "otherNumAtRisk": 125}, {"id": "EG002", "title": "Metformin 500 mg", "description": "Metformin 500 mg twice daily", "seriousNumAffected": 1, "seriousNumAtRisk": 126, "otherNumAffected": 8, "otherNumAtRisk": 126}, {"id": "EG003", "title": "Metformin 850", "description": "Metformin 850 mg twice daily", "seriousNumAffected": 1, "seriousNumAtRisk": 124, "otherNumAffected": 13, "otherNumAtRisk": 124}, {"id": "EG004", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg once daily", "seriousNumAffected": 3, "seriousNumAtRisk": 120, "otherNumAffected": 6, "otherNumAtRisk": 120}, {"id": "EG005", "title": "Placebo", "description": "Matching placebo to sitagliptin and/or metformin. Population excludes 1 participant who did not receive any study medication.", "seriousNumAffected": 1, "seriousNumAtRisk": 126, "otherNumAffected": 4, "otherNumAtRisk": 126}], "seriousEvents": [{"term": "Coagulopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 126}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Thoracic vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Coagulation time shortened", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Transaminases increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Renal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 126}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Lung infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 126}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 10, "numAffected": 9, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 3, "numAffected": 2, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 4, "numAffected": 4, "numAtRisk": 126}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 126}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 15.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 122}, {"groupId": "EG001", "numEvents": 11, "numAffected": 7, "numAtRisk": 125}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 126}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 124}, {"groupId": "EG004", "numEvents": 7, "numAffected": 4, "numAtRisk": 120}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 126}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President,Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}